Bårnes Guro K, Kristiansen Paul A, Beyene Demissew, Workalemahu Bereket, Fissiha Paulos, Merdekios Behailu, Bohlin Jon, Préziosi Marie-Pierre, Aseffa Abraham, Caugant Dominique A
WHO Collaborating Center for Reference and Research on Meningococci, Norwegian Institute of Public Health, Oslo, Norway.
Faculty of Medicine, University of Oslo, Oslo, Norway.
BMC Infect Dis. 2016 Nov 4;16(1):639. doi: 10.1186/s12879-016-1975-3.
Neisseria meningitidis colonizes humans and transmits mainly by asymptomatic carriage. We sought to determine the prevalence and epidemiology of meningococcal carriage in Ethiopia prior to the introduction of MenAfriVac, a serogroup A meningococcal conjugate vaccine.
A cross-sectional meningococcal carriage study was conducted in Arba Minch, southern Ethiopia. A total of 7479 oropharyngeal samples were collected from 1 to 29 year old volunteers, between March and October, 2014. The swabs were cultured for N. meningitidis and Neisseria lactamica in Ethiopia. N. meningitidis isolates were confirmed and characterized by their serogroup, sequence type (ST) and PorA:FetA profile in Norway.
Overall carriage prevalence was 6.6 %. There was no significant difference in overall carriage between male (6.7 %) and female (6.4 %) participants. Highest carriage prevalence (10.9 %) for females was found in the 15-19 years of age, while prevalence among males was highest (11.3 %) in the 20-24 age group. Non-groupable isolates dominated (76.4 %), followed by serogroups X (14.0 %) and W (5.9 %) isolates. No serogroup A was found. Most non-groupable isolates were ST-192. Serogroup W isolates were assigned to the ST-11 clonal complex, and serogroup X isolates to the ST-181 and ST-41/44 clonal complexes. Overall carriage prevalence of N. lactamica was 28.1 %. Carriage of N. meningitidis and N. lactamica varied depending on age and geographic area, but there was no association between carriage of the two species.
Epidemic strains of serogroups W and X were circulating in this area of Ethiopia. As no serogroup A was found among the carriage isolates the immediate impact of mass-vaccination with MenAfriVac on transmission of N. meningitidis in this population is expected to be marginal.
脑膜炎奈瑟菌在人类中定植,主要通过无症状携带进行传播。我们试图在引入A群脑膜炎球菌结合疫苗MenAfriVac之前,确定埃塞俄比亚脑膜炎球菌携带的流行情况和流行病学特征。
在埃塞俄比亚南部的阿尔巴明奇进行了一项横断面脑膜炎球菌携带研究。2014年3月至10月期间,从1至29岁的志愿者中总共采集了7479份口咽样本。在埃塞俄比亚,将拭子培养用于检测脑膜炎奈瑟菌和乳酸奈瑟菌。在挪威,脑膜炎奈瑟菌分离株通过血清群、序列类型(ST)和PorA:FetA谱进行确认和鉴定。
总体携带率为6.6%。男性(6.7%)和女性(6.4%)参与者的总体携带率无显著差异。女性携带率最高(10.9%)的年龄组为15 - 19岁,而男性携带率最高(11.3%)的年龄组为20 - 24岁。不可分组的分离株占主导(76.4%),其次是X群(14.0%)和W群(5.9%)分离株。未发现A群。大多数不可分组的分离株为ST - 192。W群分离株属于ST - 11克隆复合体,X群分离株属于ST - 181和ST - 41/44克隆复合体。乳酸奈瑟菌的总体携带率为28.1%。脑膜炎奈瑟菌和乳酸奈瑟菌的携带情况因年龄和地理区域而异,但两种菌的携带之间无关联。
W群和X群的流行菌株在埃塞俄比亚的这一地区传播。由于在携带分离株中未发现A群,预计MenAfriVac大规模接种对该人群中脑膜炎奈瑟菌传播的直接影响很小。